Quantinuum Inc. (NASDAQ: QNT) is seeking to raise approximately $1.43 billion in its initial public...
Braveheart Bio (NASDAQ: BRVE) has filed to raise approximately $300 million through an initial public offering of 18.75 million shares priced between $15.00 and $17.00 per share, implying a midpoint offering size of $300 million and a fully diluted market capitalization of approximately $1.13 billion at the midpoint. The offering is being led by Goldman Sachs, Jefferies, TD Cowen, Stifel, and Cantor.
Braveheart Bio is a clinical-stage biotechnology company developing treatments for hypertrophic cardiomyopathy (HCM), a chronic cardiovascular disease that affects more than 700,000 people in the United States. The company's lead asset, BHB-1893, is a next-generation oral cardiac myosin inhibitor designed to improve upon existing therapies by offering faster onset, simplified dosing, fewer monitoring requirements, and potentially improved cardiac safety.
The current HCM market has already been validated by Bristol Myers Squibb's Camzyos and Cytokinetics' Myqorzo, but both therapies require careful dose titration and frequent echocardiograms because reductions in heart muscle obstruction can also reduce heart pumping function. Braveheart believes BHB-1893 may offer a differentiated profile by producing strong reductions in obstruction while minimizing declines in left ventricular ejection fraction, potentially simplifying treatment for both physicians and patients.
The company's development program is built upon clinical work originally performed by Jiangsu Hengrui Pharmaceuticals, from which Braveheart licensed worldwide rights outside Greater China in 2025. More than 300 patients have been dosed with BHB-1893 globally, with Phase 2 studies demonstrating rapid reductions in left ventricular outflow tract gradients and encouraging safety observations. Braveheart expects to launch its global LIONHEART-HCM Phase 3 trial during the second half of 2026, followed by the NOBLEHEART-HCM Phase 3 program in non-obstructive HCM during the first half of 2027.
Financially, Braveheart remains a pre-revenue biotechnology company focused almost entirely on research and development. The company reported a 2025 net loss of $66.1 million, while first-quarter 2026 net loss totaled $14.3 million. Cash and cash equivalents stood at $80.6 million as of March 31, 2026, which management expects to increase substantially following the IPO. At the midpoint pricing assumption, net proceeds are expected to total approximately $274.5 million, funding both planned Phase 3 programs along with continued clinical operations and general corporate purposes.
One notable feature of the offering is a non-binding indication of interest from Fidelity Management & Research to purchase up to $75 million of shares in the IPO, representing roughly one-quarter of the offering at the midpoint if fully allocated. While not a binding commitment, cornerstone participation from a large institutional investor often provides additional confidence during the book-building process.
Braveheart enters the public markets at a time when investor interest in cardiovascular innovation remains strong. Rather than competing by introducing an entirely new treatment class, the company is attempting to build a best-in-class therapy within an already commercialized market. Success will ultimately depend on whether Phase 3 studies can confirm the promising efficacy and safety profile observed in earlier clinical work, but the opportunity addresses a large and established cardiovascular market with significant unmet need.
